These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 22849533)
41. Torticollis after low-dose aripiprazole administration in a Thai schizophrenia patient. Ittasakul P; Srivastava S; Hiranyatheb T; Ketter TA Asian J Psychiatr; 2012 Dec; 5(4):365-6. PubMed ID: 23174451 [No Abstract] [Full Text] [Related]
42. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder--a systematic review. Deb S; Farmah BK; Arshad E; Deb T; Roy M; Unwin GL Res Dev Disabil; 2014 Mar; 35(3):711-25. PubMed ID: 24405794 [TBL] [Abstract][Full Text] [Related]
43. An open-label assessment of aripiprazole in the treatment of PTSD. Robert S; Hamner MB; Durkalski VL; Brown MW; Ulmer HG Psychopharmacol Bull; 2009; 42(1):69-80. PubMed ID: 19204652 [TBL] [Abstract][Full Text] [Related]
44. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. Budman C; Coffey BJ; Shechter R; Schrock M; Wieland N; Spirgel A; Simon E J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):509-15. PubMed ID: 18928415 [TBL] [Abstract][Full Text] [Related]
46. A systematic review of medical treatments for children with autism spectrum disorders. McPheeters ML; Warren Z; Sathe N; Bruzek JL; Krishnaswami S; Jerome RN; Veenstra-Vanderweele J Pediatrics; 2011 May; 127(5):e1312-21. PubMed ID: 21464191 [TBL] [Abstract][Full Text] [Related]
47. Priapism associated with oxcarbazepine, aripiprazole, and lithium. Negin B; Murphy TK J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1223-4. PubMed ID: 16292111 [No Abstract] [Full Text] [Related]
48. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. Masi G; Cosenza A; Millepiedi S; Muratori F; Pari C; Salvadori F CNS Drugs; 2009; 23(6):511-21. PubMed ID: 19480469 [TBL] [Abstract][Full Text] [Related]
49. Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder. Findling RL; Youngstrom EA; McNamara NK; Stansbrey RJ; Wynbrandt JL; Adegbite C; Rowles BM; Demeter CA; Frazier TW; Calabrese JR J Clin Psychiatry; 2012 Jan; 73(1):57-63. PubMed ID: 22152402 [TBL] [Abstract][Full Text] [Related]
50. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study. Jon DI; Kim DH; Seo HJ; Kwon YJ; Kim MD; Yang JC; Suh HS; Min KJ; Pae CU; Bahk WM Clin Neuropharmacol; 2013; 36(5):157-61. PubMed ID: 24045606 [TBL] [Abstract][Full Text] [Related]
51. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. Barzman DH; DelBello MP; Kowatch RA; Gernert B; Fleck DE; Pathak S; Rappaport K; Delgado SV; Campbell P; Strakowski SM J Child Adolesc Psychopharmacol; 2004; 14(4):593-600. PubMed ID: 15662152 [TBL] [Abstract][Full Text] [Related]
52. Aripiprazole in the treatment of bipolar disorder in children and adolescents. Durkin JP J Child Adolesc Psychopharmacol; 2004; 14(4):505-6. PubMed ID: 15662141 [No Abstract] [Full Text] [Related]
53. An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with conduct disorder. Kuperman S; Calarge C; Kolar A; Holman T; Barnett M; Perry P Ann Clin Psychiatry; 2011 Nov; 23(4):270-6. PubMed ID: 22073384 [TBL] [Abstract][Full Text] [Related]
54. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Marder SR; McQuade RD; Stock E; Kaplita S; Marcus R; Safferman AZ; Saha A; Ali M; Iwamoto T Schizophr Res; 2003 Jun; 61(2-3):123-36. PubMed ID: 12729864 [TBL] [Abstract][Full Text] [Related]
55. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. Glick ID; Poyurovsky M; Ivanova O; Koran LM J Clin Psychiatry; 2008 Dec; 69(12):1856-9. PubMed ID: 19026264 [TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of aripiprazole in child and adolescent patients. Kirino E Eur Child Adolesc Psychiatry; 2012 Jul; 21(7):361-8. PubMed ID: 22447196 [TBL] [Abstract][Full Text] [Related]
57. Micturition difficulty and urinary retention associated with aripiprazole and citalopram treatment in a male adolescent with Asperger syndrome. Yalcin O J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):598-9. PubMed ID: 24511913 [No Abstract] [Full Text] [Related]
58. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811 [TBL] [Abstract][Full Text] [Related]
59. Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder. Jordan I; Robertson D; Catani M; Craig M; Murphy D Psychopharmacology (Berl); 2012 Oct; 223(3):357-60. PubMed ID: 22535309 [TBL] [Abstract][Full Text] [Related]
60. Aripiprazole in autism spectrum disorders and fragile X syndrome. Erickson CA; Stigler KA; Posey DJ; McDougle CJ Neurotherapeutics; 2010 Jul; 7(3):258-63. PubMed ID: 20643378 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]